Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.53 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.53 |
| ▸ | CNR1 | P21554 | 3/20 | 0.51 |
| ▸ | CNR2 | P34972 | 2/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL89061 | 0.90 | KMT2A (0.56) | KMT2APOLBMTNR1BMTNR1ACNR1 | |
| SCHEMBL1911374 | 0.88 | KMT2A (0.54) | KMT2APOLBMTNR1BMTNR1ACNR1 | |
| SCHEMBL15087924 | 0.88 | KMT2A (0.54) | KMT2APOLBMTNR1BMTNR1ACNR1 | |
| SCHEMBL90347 | 0.88 | KMT2A (0.54) | KMT2APOLBMTNR1BMTNR1ACNR1 | |
| SCHEMBL89611 | 0.81 | TSHR (0.51) | KMT2APOLBMTNR1BMTNR1ACNR1 | |
| SCHEMBL13625698 | 0.81 | ENPP2 (0.54) | POLBCNR1 | |
| SCHEMBL3931955 | 0.79 | KMT2A (0.51) | KMT2APOLBL3MBTL1MEN1 | |
| SCHEMBL4305918 | 0.77 | CNR1 (0.45) | POLBCNR1CNR2L3MBTL1KDM4E | |
| SCHEMBL4309070 | 0.77 | CNR1 (0.45) | POLBCNR1CNR2L3MBTL1KDM4E | |
| SCHEMBL13753200 | 0.77 | MTNR1B (0.75) | KMT2AMTNR1BMTNR1AL3MBTL1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129411-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-03-06 | — | — | US | disclosed |
| US-8129411-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-03-06 | — | — | US | disclosed |
| EP-2420491-A1 | 3 , 5-substitued piperidine compounds as renin inhibitors | Novartis AG (CH) | 2012-02-22 | — | — | EP | disclosed |
| US-20090192148-A1 | Organic Compounds | NOVARTIS AG (CH) | 2009-07-30 | — | — | US | disclosed |
| US-20090192148-A1 | Organic Compounds | NOVARTIS AG (CH) | 2009-07-30 | — | — | US | disclosed |
| WO-2007077005-A1 | 3 , 5-SUBSTITΓUED PIPERIDINE COMPOUNDS AS RENIN INHIBITORS | NOVARTIS AG (CH) | 2007-07-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192148-A1 | Organic Compounds | REN, ACE, AGTR1 | KMT2A 3129/4885POLB 589/4885MTNR1B 692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.